

Paper Ref TB21.015

Meeting Title Trust Board Meeting in Public	Meeting Date 27 April 2021
Reporting Committee	Quality Committee
Committee Chaired By	Tim Gilpin, Non-Executive Director
Lead Executive Director	Steve Page, Executive Director of Quality, Governance and Performance Assurance/ Deputy Chief Executive
Date of Last Committee Meeting[s]	11 March 2021

Summary of Key Matters Considered and Decisions Taken

The Committee has held one meeting since its last report to the Board. The meeting was held via videoconference and was quorate.

- The Clinical Governance and Quality Report was presented which included a review of the 2020/21 Quality Accounts. The Trust was contributing to the National Ambulance Safeguarding Assurance Group (NASAG) to undertake a scoping exercise to address the national picture of Vulnerable children accessing Emergency and Urgent care services as a solution focused whole system approach in order to meet Statutory responsibilities.
- The Committee held a discussion around the safety of intravenous (IV) paracetamol and these concerns will be taken to the next governance group and nationally to seek clarification.
- The Committee received the Regulatory Compliance Report with particular attention to the reporting of injuries, diseases and dangerous occurrences regulations (RIDDOR). Advice provided to the Trust by a local HSE Inspector confirmed that a COVID RIDDOR report should only be made where there is "strong evidence" that exposure is work related.
- An update was presented on significant events and lessons learned. A case was presented on a delayed response to a 999 call.
- Members received an update on Freedom to Speak up activities, noting the policy and procedures will be reviewed and updated over the next few months.
- Presentations were given on the Service Line Assurance in PTS; IUC and A&E (performance; developments; risks and mitigations.). One of the main concerns in IUC was the significant reduction in demand since December 2020. The level of A&E sickness and staff absences in EOC would be reviewed and monitored.
- The key points highlighted in respect of the Workforce & OD report, included: 37% response rate for Staff Survey, the Trust winning Gold on Learning Programme for Paramedic Apprenticeships and best programme of year with Learning & Performance.
- The Committee also received reports for Risk Management, Clinical Development and Innovation and Quality Improvement.
- It was agreed that the Committee would hold two meetings per quarter.



Risks Identified / Matters of Concern and Mitigating Actions

• ECA recruitment to be increased. 68 FTE ECA currently in training yet to go out to Operations 76 candidates in the pipeline progressing checks, beginning to fill courses for Q1 202. To manage the risk of extended starting timescales, communication updates have been sent to candidates to keep them up to date with the latest information and expectations managed ECA offer process now more flexible, sending candidates an 'initial offer' to complete their C1, then progressing with employment checks is working well.

Matters for Escalation to the Board

• The safety of intravenous (IV) paracetamol will be taken to the next governance group and nationally to seek clarification for the Board.

Please note this is the latest update in the CEO Report for Board : IPR exceptions:

The segment elevation myocardial infarction (STEMI) care bundle compliance remains low at 44% (January 2021) due to a historical decision by YAS not to include the administration of paracetamol as a valid analgesic in the management of cardiac chest pain, despite this being included as an option in the national Clinical Quality Indicator. Non-Executive Directors have challenged the validity of this approach and have requested a review of the evidence that led to the YAS decision. A rapid literature review is underway, and the Medical Director is to request a review of the validity of paracetamol as an analgesic for the management of cardiac chest pain with NASMeD.

Date of next Committee Meetings

03 June 2021 and 17 June 2021